Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

Summary

This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.

Timeline

Start

2014-03-27

Primary completion

2016-03-22

Completion

2016-03-22

Outcome

Outcome not reported

Stopped: “The study was prematurely terminated after core study CQGE031B2201 failed to meet the primary objective of demonstrating superiority for QGE031 versus placebo.”

Drugs

Indications